DexCom
- Market cap
- 31.81B
- P/E (TTM)i
- 33.32
- P/Bi
- 12.13
- EPSi
- 2.09
- Div yieldi
- 0.00%
- 52W posi
- 78%
Anonymous reader poll. Unscientific, not investment advice.
DexCom ended the session at 84.30, up 1.09%. Its market capitalisation is about 31.81B, the #635 most valuable US-listed company we track. Valuation-wise, the P/E sits at 34.11, 68% below the five-year average of 107.84. Wall Street's 19-analyst consensus lands on Buy, with a price target averaging 93.76 (+11% from here). The shares sit 78% of the way up their 52-week range of 54.11 to 92.59.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 2 months.
- Recent price momentum is +21.1% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation C
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 34.3x | Better than 22% |
| Forward P/E | 30.5x | Better than 20% |
| Price / Sales | 6.6x | Better than 20% |
| P/E vs own 5-yr range | 10th pctl | Better than 87% |
Growth A
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 17.0% | Better than 80% |
| Net income CAGR (3Y) | 34.8% | Better than 85% |
| Free cash flow CAGR (3Y) | 52.3% | Better than 87% |
Profitability A-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 60.1% | Better than 75% |
| Operating margin | 19.6% | Better than 63% |
| Net margin | 17.9% | Better than 70% |
| Return on equity | 34.5% | Better than 82% |
| Return on invested capital | 17.3% | Better than 79% |
Momentum A
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 18.1% | Better than 86% |
| 6-month return | 37.7% | Better than 85% |
| 12-month return (ex latest month) | 32.5% | Better than 68% |
| Distance below 52-week high | 6.1% | Better than 88% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.9x | Better than 65% |
| Debt to assets | 21.9% | Better than 61% |
| Interest coverage | 60.5x | Better than 90% |
| Free cash flow / net income | 128.8% | Better than 62% |
Analyst View B-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 94.7% | Better than 79% |
| Upside to average target | 7.9% | Better than 13% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 83.39
- Open
- 83.81
- Day range
- 83.74 - 85.70
- Avg price
- 84.45
- Volume
- 2.86M
- Turnover
- 241.86M
- Turnover ratei
- 0.76%
- Volume ratioi
- 0.93
- Amplitudei
- 2.34%
- 52-week rangei
- 54.11 - 92.59
Valuation
- P/Ei
- 40.33
- P/E (TTM)i
- 33.32
- P/Bi
- 12.13
- EPSi
- 2.09
- Book value / shi
- 6.95
- Net profit
- 788.68M
- Net assets
- 2.62B
Share structure
- Market cap
- 31.81B
- Float capi
- 31.70B
- Shares out
- 377.36M
- Float sharesi
- 376.00M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2005-04-14
9.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-354.96M net over the window
Short interest
- Shares short
- 17.26M
- % of floati
- 4.57%
- Days to coveri
- 4.98
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of DexCom (DXCM)?
DexCom last traded at 84.30. The quote on this page refreshes every few seconds while US markets are open.
What is DexCom's market cap?
About 31.81B.
What is the P/E ratio of DexCom?
The trailing twelve-month P/E is 33.32, below its own 5-year average of 107.84 — toward the bottom of its historical range (10.45% percentile). See the Valuation tab for the full history.
Does DexCom pay a dividend?
DexCom does not currently pay a regular dividend.
Is DexCom a buy according to analysts?
The consensus of 19 analysts is a Buy rating, with an average 12-month price target of 93.76, which implies 11.2% upside from the current price. This is not investment advice.
What is DexCom's StockVane Quant Rating?
The StockVane Momentum strategy currently rates DexCom a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-10-08 04:00:02 · For reference only, not investment advice and not tailored to your situation.